Abstract: The present invention is directed respirable, dry powder particle formulations of lung surfactants that optionally comprise surfactant proteins and that are formulated for delivery to the pulmonary system via inhalation.

Abstract: CER-001 for treating kidney disease, and methods for treating a subject having kidney disease with CER-001.

Abstract: An object is to provide a prebiotic which efficiently proliferates a butyrate-producing bacterium. An oligosaccharide which is composed of ?-D-mannuronic acid and/or ?-L-guluronic acid and which has an unsaturated form of ?-D-mannuronic acid residue or ?-L-guluronic acid residue at the non-reducing end or a salt thereof is used as an active ingredient of a prebiotic composition for a butyrate-producing bacterium. The oligosaccharide can be produced by causing an alginate lyase to act on alginic acid and/or a salt thereof or a hydrolysate thereof and thus obtaining a degradation product of alginic acid.

Abstract: The drugs available for the treatment of cutaneous leishmaniasis have unsatisfactory efficacy, frequent and serious adverse effects, and require long treatment regimens. Thus, the search for new treatment alternatives for cutaneous leishmaniasis is considered a priority by the World Health Organization. Parenteral administration of pentavalent antimonials for the treatment of all forms of leishmaniasis, including cutaneous leishmaniasis, has several limitations. The therapy is long, requires repeated doses, and adverse reactions are frequent. Topical treatment is an attractive alternative for cutaneous leishmaniasis, offering significant advantages over systemic therapy: fewer adverse effects, ease of administration, and lower costs. The present inventors aimed to provide a fixed-dose topical composition containing at least one antileishmanial compound, providing adequate absorption of the active ingredient.

Abstract: Provided herein are compositions and methods of reducing adduct formation.

Abstract: In one aspect, the present disclosure provides GlcNAc-Asn analogs of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of using the compounds disclosed herein. Additionally, the present disclosure also provides methods of treating cancer comprising inhibiting NGLY1.

Abstract: This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Abstract: The invention concerns biocompatible polymer systems comprising at least one polymer with a plurality of pores, said polymer comprising a sulfonic acid salt functionality designed to adsorb a broad range of protein based toxins from less than 0.5 kDa to 1,000 kDa and positively charged ions including but not limited to potassium.

Abstract: The invention provides one or more agent selected from organic carboxylic acids, organic non-carboxylic reducing acids, nitric oxide (NO), a nitric oxide generating composition, a combination or combinable association of ingredients for a nitric oxide generating composition, and mixtures thereof, for use as an antiviral agent against SARS-CoV or SARS-CoV-2 coronavirus.

Abstract: A dialysate for hemodialysis contains electrolyzed hydrogen water, has a dissolved hydrogen concentration of 100 ppb to 200 ppb, and has an activity of reducing a feeling of fatigue.

Abstract: A new superfine powder of selenium disulfide with a particle size in the range of 1-50 ?m and the particle size distribution with D90 of (1.0˜15.0) ?m, and its application in lotion products, are provided in the present invention. Compared with the prior art, the superfine powder of selenium disulfide in the present invention is beneficial to the preparation of the selenium disulfide lotion product and the improvement of the quality of the selenium disulfide lotion product.

Abstract: The present invention relates to an antimicrobial agent composition comprising an undiluted mixture solution formed by mixing: 1 to 10 wt % of a mixture comprising 50 to 60 wt % of purified water and chloride in which sodium chloride and calcium chloride which are at a 1:1 ratio are contained; 1 to 2 wt % of a mixture comprising Pueraria lobata root extract and bellflower root extract which are selected from among natural extracts and are at a 1:1 ratio; 5 to 10 wt % of a mixture comprising carbonate based material in which sodium carbonate and sodium bicarbonate which are at a 1:1 ratio are contained; 10 to 15 wt % of a mixture comprising lactic acid and acetic acid among organic acids and their related salts, which are at a 1:1 ratio; and 5 to 10 wt % of chloric acid based compound of inorganic acid.

Abstract: The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets.

Abstract: The present invention relates to compositions and their use for oral care. In particular, the compositions and methods are for maintaining oral health and/or treating various oral conditions such as gingivitis. The present invention relates to methods and uses of stabilized amorphous calcium phosphate (ACP) and/or stabilized amorphous calcium fluoride phosphate (ACFP) in the preparation of a medicament for reducing pathogenic oral bacteria at an oral site in an individual; increasing commensal oral bacteria at an oral site in an individual; decreasing the proportion of pathogenic oral bacteria at an oral site in an individual; inhibiting oral dysbiosis; reducing gingival inflammation in an individual in need thereof; treating gingivitis in an individual in need thereof; and treating chronic gingivitis in an individual in need thereof.

Abstract: The present invention relates to a novel T-cell receptor binding to MR1, and a use thereof. Unlike a conventional customized anticancer immune T cell therapeutic agent, which are limitedly used depending on cancer type and the expression of cancer antigens according to human leukocyte antigen (HLA) type, T cells in which a T-cell receptor is expressed can be applied to all types of cancer regardless of HLA type.

Abstract: Provided herein, inter alia, are compositions including engineered NK cells and methods for preparing the same. The engineered NK cells provided herein include integrated nucleic acid sequences encoding Cas9 proteins (e.g. dCas9). The engineered NK cells are contemplated to be effective for treating and/or preventing cancer, particularly leukemia.

Abstract: The invention relates to the field of cancer immunotherapy by employing bicistronic inhibitory chimeric antigen receptor (iCAR)/activating chimeric antigen receptor (aCAR) constructs for use in cancer treatment therapies.

Abstract: The present disclosure relates to methods, compositions and uses involving immunotherapies and inhibitors of a target protein tyrosine kinase in which the kinase is not IL-2-inducible T cell kinase (ITK) and/or is selected from Bruton's tyrosine kinase (BTK), tec protein tyrosine kinase (TEC), BMX non-receptor tyrosine kinase (Etk), TXK tyrosine kinase (TXK) and/or receptor tyrosine-protein kinase ErbB4 (ErbB4). The provided methods, compositions and uses include administration of one or more such inhibitor with another agent, such as an immunotherapeutic agent targeting T cells and/or genetically engineered T cells, such as CAR-expressing T cells. Also provided are methods of manufacturing engineered cells, cells, compositions, methods of administration, nucleic acids, articles of manufacture and kits.

Abstract: ?? T cells comprising a molecule comprising (i) a target-specific antigen-binding domain, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided.

Abstract: Provided are a preparation method and an application of CD7-CAR-T cells. The method comprises: (i) providing a sample to be processed containing T cells, (ii) sorting and activating the T cells contained in the sample, so as to obtain activated T cells, (iii) introducing a first viral vector for expressing a CD7 blocking molecule into the activated T cells, so as to obtain CD7 blocked T cells, and (iv) introducing a second viral vector for expressing a CD7-CAR into the CD7-blocked T cells to obtain CD7-CAR-T cells. By adjusting the transfection sequence and transfection time of the lentivirus expressing the CD7 blocking molecule and the lentivirus expressing the CD7-CAR, transfection efficiency is improved, and the cytotoxicity of the CAR-T cells is enhanced.

Abstract: A CAR-immunocyte targeting an NKG2D ligand can be used in the preparation of a drug. The drug is used for: (i) removing the senescent cell, the NKG2D ligand in the senescent cell being up-regulated by 2-20 times, preferably 4-15 times, more preferably 10-20 times the normal cell; (ii) delaying individual senescence; and/or (iii) preventing and/or treating age-related diseases. The CAR-immunocyte targeting the NKG2D ligand is capable of specifically removing the senescent cell having high expression of the NKG2D ligand, and has higher in-vivo security.

Abstract: Methods of treating cancer with a precision genome engineered NeoTCR Product are described herein.

Abstract: Treatment of rheumatoid arthritis has been revolutionized by the introduction of TNF-alpha blockers, which represent a 40 billion dollar annual market. Unfortunately, a significant proportion of patients fail to respond to these treatments. The current invention provides the use of stem cell conditioned T cells to overcome resistance to TNF-alpha blockers by concurrently providing a source of immune modulatory and regenerative cells that synergize with TNF-alpha blockers.

Abstract: Provided herein are PD-1 chimeric cytokine receptors. When present on chimeric antigen receptor (CAR)-bearing immune cells, such receptors allow for increased immune cell activation, proliferation, persistence, and/or potency, when engaged with PD-1 ligands or activation with an anti-PD-1 antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.

Abstract: A system combining programmable bacteria cells that produce one or more antigens and optionally one or more cytokines and CAR-T cells that recognize and respond to at least one of the antigens to elicit an immune response against tumors and treat hyperproliferative disorders.

Abstract: The present invention includes compositions and methods for treating heart disease and/or heart failure. In one embodiment, the treatment includes administering to the subject a cell genetically modified to express a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for fibroblast activation protein (FAP). In another embodiment, the treatment includes administering a cell genetically modified to express a T cell receptor (TCR) specific for an activated fibroblast.

Abstract: The present application is directed to methods and compositions that are useful for reducing the number of myeloid-derived suppressor cells (MDSC), tumor associated macrophages (TAM), or both in a subject. The methods include administering an antigen binding protein that binds to an antigen expressed by MDSC and/or TAM, or administering a modified T cell or NK-92 cell that expresses an antigen binding protein that binds to an antigen expressed by MDSC and/or TAM, or a combination of both, to a subject. For example, the antigen binding protein can bind to CD33 expressed by MDSC and/or TAM. The methods and compositions are useful for treating a disease associated with MDSC and/or TAM infiltration into a tissue or tumor.

Abstract: A cell-nanoparticle drug delivery system includes mesenchymal stem cells and gadolinium-based agent-loaded magnetic nanoparticles which are internalized into the mesenchymal stem cells. Each of the gadolinium-based agent-loaded magnetic nanoparticles includes a core that is loaded with gadolinium-based agent and that includes a fucoidan-based inner core layer with the fucoidan non-covalently bound to the gadolinium-based agent, and a shell which includes superparamagnetic iron oxide-based inner shell layer with the superparamagnetic iron oxide bound to the gadolinium-based agent through electrical attraction, and an outer shell layer made of fucoidan and polyvinyl alcohol. Methods for inhibiting the growth of tumor cells and diagnosing the tumor cells in a subject using the cell-nanoparticle drug delivery system are also provided.

Abstract: A device that allows for either fat graft preparation or cell fraction harvest is disclosed. The device includes a first centrifuge tube configured to receive and process a biological substance, the first centrifuge tube comprising an upper cylindrical portion and a lower conical portion, a sterile tissue inlet fitting, at least one sterile processing fluid inlet fitting, a sterile suction fitting, and at least one sterile extraction port connected to a first extraction tube. The first centrifuge tube further includes an internal space including a screen being positioned therein, the screen being configured to divide the internal space in half, and a filter positioned therein, the filter being positioned below the screen in the lower conical portion of the first centrifuge tube. The device may further include a second centrifuge tube configured to receive and further process the biological substance from the first centrifuge tube.

Abstract: The present invention discloses the application of retinal pigment epithelial cells for replacing corneal endothelial cells, preventing and treating diseases or symptoms such as corneal endothelial functional decompensation. The retinal pigment epithelial cell suspension provided by the present invention can restore corneal transparency, reduce corneal thickness, reconstruct corneal endothelial barrier function, effectively treat corneal endothelial functional decompensation, and has a wide range of application values and positive social benefits for the treatment or recovery of people with visual impairment due to corneal injury.

Abstract: The present invention provides a modified induced pluripotent stem cell iPSC or haemogenic lineage cell comprising at least one heterologous nucleic acid sequence encoding a heterologous T-cell receptor (TCR) integrated in the cell genome and uses thereof.

Abstract: A method of producing a bioextract from a snake fish comprising steps of selecting of a snake fish, cleaning the snake fish, reducing the snake fish down to manageable pieces by cutting, milling the snake fish, utilizing an extracting process of the milled pulp, utilizing a drying process of the extract filtrate with a combination of maltodextrin DE 10-12, powering the solidified bioextract after drying, and applying the filtered bioproduct to an industrial use. An extraction process of a snake fish may be described which may include the steps of combining a snake fish pulp with purified water and ethanol, having a concentration of about 96%, to make an extraction medium and placing the extraction medium into an extraction machine and waiting about 24 hours. Additionally described herein may be various formulations of a powered bioextract from snake fish, Moringa extract, and/or Curcuma extract.

Abstract: The global emergence of drug-resistant bacteria leads to the loss of efficacy of our antibiotics arsenal and severely limits the success of currently available treatments. Here, the inventors developed an innovative strategy based on Targeted-Antibacterial-Plasmids (TAPs) that use bacterial conjugation to deliver CRISPR/Cas systems exerting a strain-specific antibacterial activity. TAPs are highly versatile as they can be directed against any specific genomic or plasmid DNA using the custom algorithm (CSTB) that identifies appropriate targeting spacer sequences. The inventors demonstrate TAPs ability to induce strain-selective killing by introducing lethal DSBs into the targeted genomes. TAPs directed against a plasmid-born carbapenem resistance gene efficiently resensitize the strain to the drug.

Abstract: A method and system for modulating an individual's microbiome in a manner such that individuals who are overweight, obese and/or suffer from cardiometabolic diseases and/or inflammatory bowel diseases are able to reduce the incidence of chronic conditions and diseases associated therewith. Certain embodiments are directed to a method and bacterial formulations for reducing the likelihood of developing NAFLD and NASH.

Abstract: Methods of treating an environmental surface by depositing a preparation including nonpathogenic bacteria on the environmental surface are disclosed. Methods of treating an environmental surface by depositing a preparation including ammonia oxidizing microorganisms on the environmental surface are disclosed. Methods of introducing nonpathogenic bacteria into a built environment are disclosed. Methods of introducing ammonia oxidizing microorganisms into a built environment are disclosed. Methods of modulating a microbiome associated with a built environment or maintaining a microbiome associated with a built environment are disclosed. Methods of treating a subject by introducing ammonia oxidizing microorganisms into the built environment are also disclosed.

Abstract: Provided are nucleic acids that include a promoter, where the promoter is operable in a Bacteroides cell and is operably linked to a heterologous nucleotide sequence of interest. Also provided are nucleic acids that include a promoter (operable in a prokaryotic cell such as a Bacteroides cell) operably linked to a sequence encoding a synthetic ribosomal binding site (RBS). Also provided are fusion proteins (and nucleic acids encoding them) in which a secreted Bacteroides polypeptide is fused to a heterologous polypeptide of interest. Also provided are prokaryotic cells (e.g., E. coli, a Bacteroides cell, and the like) that include one more nucleic acids such as those described above. Also provided are methods of expression in a prokaryotic cell, methods of detectably labeling a Bacteroides cell in an animal's gut, and methods of delivering a protein to an individual's gut.

Abstract: The present invention generally provides methods and compositions for the treatment of Parkinson's disease, Alzheimer's disease, depression, anxiety, and memory deficits. The invention relates to recombinant microorganisms, particularly gut-colonizing probiotics, modified to produce L-DOPA as well as microcapsules and lyophilized formulations comprising the same.

Abstract: Disclosed are a Bacillus coagulans and its application for improving constipation, belonging to the field of microbial strains. The Bacillus coagulans disclosed in the present application is preserved in China General Microbiological Culture Collection Center (CGMCC) on Nov. 10, 2021, with a preservation number of CGMCC No. 23766 and a preservation address of the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard No. 1 Beichen West Road, Chaoyang District, Beijing.

Abstract: The invention provides a combination therapy comprising a bacterial strain for treating or preventing cancer.

Abstract: The present disclosure relates to administration of carotenoids to provide a prebiotic effect for modification of gut microbiome, thereby increasing counts of Bifidobacterium adolescentis and/or decreasing counts of pathology-associated bacteria from phylum Bacteroidetes, and its particular genus Prevotella, and also genera from other phyla such as Desulfovibrio and Dialister, and resulting in improved systemic effects.

Abstract: Lactobacillus johnsonii is provided. The Lactobacillus johnsonii is Lactobacillus johnsonii TCI369 with an accession number of DSM 34008. Also, a method for increasing the level of unsaturation in fatty acids is provided. The method includes administering to a subject in need thereof a composition including Lactobacillus johnsonii or metabolites thereof. The Lactobacillus johnsonii is the Lactobacillus johnsonii TCI369 with an accession number of DSM 34008.

Abstract: Lactiplantibacillus plantarum TCI837 is provided, deposited in the Leibniz Institute DSMZ under an accession number of DSM 33843. Based on this, a method for improving gut microbiota in a subject in need thereof is also provided, comprising administering to the subject a composition comprising an effective dose of Lactiplantibacillus plantarum TCI837, wherein improving the gut microbiota comprises increasing probiotics and reducing non-probiotics.

Abstract: This disclosure relates to modified viruses, e.g., oncolytic vaccinia viruses, which have been modified to contain an exogenous nucleic acid that expresses a protein that modulates STAT3 activity. It is based, at least in part, on the discovery that vaccinia viruses modified to contain nucleic acid encoding PIAS3 and that express PIAS3 or a fragment thereof can inhibit STAT3 activity and enhance the anti-cancer activity of the vaccinia virus. Accordingly, this disclosure provides for oncolytic vaccinia viruses and methods of using them in the treatment of cancers.

Abstract: A food supplement is composed of a water-insoluble extract of a microalga and at least one oil selected from medium-chain triglycerides (MCT), wherein the extract of microalga comprises at least 25 mg/g of one or several omega-3 type fatty acid(s), at least 5 mg/g of one or several xanthophyll(s), at least 0.5 mg/g of one or several sterol(s) and at least 1 ?g/g of one or several phycoprostane(s). A method for preventing the apparition of age-related cognitive disorders, defined as a non-pathological decrease of the cognitive functions, or cognitive disorders in children or young adults having been subjected to a prenatal stress inducing non-pathological disorders, such as hyperactivity, attention and memory deficit, language retardation and anxious behavior, involves administration of an effective amount of the food supplement to a human in need thereof.

Abstract: A method of producing a cannabis infused product that includes creating a cannabis and alcohol mixture that is filtered and frozen to create a green dragon extract that is combined with a proportional amount of sugar and baked together and dried to form the cannabis infused product. Furthermore, the instant method includes labeling the final product with information defining the medicinal qualities of the product based upon the color of the final product.

Abstract: A novel device and method of use featuring color-coded or otherwise distinguishable cannabis containing products wherein the color or distinguishable feature identifies the strain of cannabis contained in the item wherein users make their selection according to the type of strain desired and what type of effect it may have upon the user.

Abstract: Methods of precision dosing matter is provided. The matter, such as plant or fungi matter, include species having or lacking active mind alternating compounds. Various extraction methods are performed to remove these compounds, such that additional compounds of predetermined dosages may be added to the plant or fungi matter until a desired level of compound concentration is reached. Homogenizing and testing is carried out at various points to ensure accurate compound concentration levels.

Abstract: The present invention relates to the manufacture of a Cannabis concentrate from dried, destemmed, and optionally ground Cannabis obtained via a closed-loop extraction using butane or propane. Another aspect of the present invention relates to a process of exposing dried, destemmed, and optionally ground Cannabis obtained via sequential CO2 and closed-loop extraction using butane or propane. Another aspect of the present invention relates to exposing Cannabis biomass to a polar solvent, filtering, then evaporating the solvent to form an extract. The solvents are then removed, for instance using heat and vacuum. Another aspect of the invention relates to compositions, such as Cannabis concentrates, that can be obtained through the processes described.

Abstract: The present invention refers to a furocoumarin-rich extract for use as antimicrobial substance, drug or medicament which comprises an extract of Angelica archangelica. The invention also refers to a non-toxic Angelica plant species furocoumarin-rich extract produced by a described method and to a said method of producing the extract. The Angelica archangelica furocoumarin-rich extract produced as described has shown a marked significant in vitro cytoprotective effect in SARS-CoV-2-exposed Vero E6 cellular cultures. The non-toxic furocoumarin-rich extract may be used for treating pathogenic infections of nucleic acid-regulated microbiome including but not restricted to virus, bacteria, parasites and fungus affecting animals and human beings.

Abstract: Provided is a composition for preventing or ameliorating bromhidrosis, including a seed fermentation product of a plant belonging to the genus Lotus. The composition may inhibit production of substances related to bromhidrosis by reducing proportions of microorganisms of the genus Corynebacterium and the genus Anaerococcus, which are related to bromhidrosis, in the microbiome.